妇乐片联合氟罗沙星治疗慢性盆腔炎的临床研究

Clinical study on Fule Tablets combined with fleroxacin in treatment of chronic pelvic inflammatory disease

目的探讨妇乐片联合氟罗沙星治疗慢性盆腔炎的临床疗效。方法选取济源市中医院2016年3月—2018年3月收治的慢性盆腔炎患者114例,随机分成对照组和治疗组,每组各57例。对照组口服氟罗沙星胶囊,0.2g/次,1次/d;治疗组在对照组的基础上口服妇乐片,5片/次,2次/d,两组均连续服用3周。观察两组患者临床疗效,同时比较治疗前后两组患者包块直径和盆腔积液深度、血清粒细胞–巨噬细胞集落刺激因子(GM-CSF)和转化生长因子-β1(TGF-β1)水平及临床症状积分。结果治疗后,对照组临床有效率为73.68%,显著低于治疗组的92.98%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组包块直径、盆腔积液深度明显减小(P<0.05),且治疗后治疗组明显小于对照组(P<0.05)。治疗后,两组血清GM-CSF水平明显降低(P<0.05),血清TGF-β1水平明显升高(P<0.05),且治疗后治疗组GM-CSF和TGF-β1水平明显优于对照组(P<0.05)。治疗后,两组患者临床症状积分显著降低(P<0.05),且治疗组临床症状积分明显低于对照组(P<0.05)。结论妇乐片联合氟罗沙星治疗慢性盆腔炎患者临床疗效确切,可显著缓解患者临床症状,且安全性较高。

Objective To investigate the effect of Fule Tablets combined with fleroxacin in treatment of chronic pelvic inflammatory disease. Methods Women（114 cases） with chronic pelvic inflammatory disease in Jiyuan Hospital of TCM from March 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 57 cases. Women in the control group were po administered with Fleroxacin Capsules, 0.2 g/time, once daily, and they were continuously treated for 3 weeks in non menstrual period. Women in the treatment group were po administered with Fule Tablets on the basis of the control group, 5 tablets/time, twice daily, and they were treated for 5 weeks. After treatment, the clinical efficacy was evaluated, and the mass diameter and the pelvic effusion depth, GM-CSF, and TGF-β1 levels, the clinical symptom scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.68%, which was significantly lower than 92.98% in the treatment group, and there were differences between two groups（P〈0.05）. After treatment, the mass diameter and the pelvic effusion depth in two groups were significantly decreased（P〈0.05）, and which in the treatment group were significantly less than those in the control group（P〈0.05）. After treatment, serum GM-CSF levels in two groups were significantly decreased（P〈0.05）, but TGF-β1 levels were significantly increased（P〈0.05）, and the GM-CSF and TGF-β1 levels in the treatment group were significantly better than those in the control group（P〈0.05）. After treatment, the clinical symptom scores in two groups were significantly decreased（P〈0.05）, and the scores in the treatment group were significantly lower than that in the control group（P〈0.05）. Conclusion Fule Tablets combined with fleroxacin in treatment of chronic pelvic inflammatory disease has significant clinical effect, which can significantly relieve the clinical symptoms with high safety.